Who won big at #AACR18? Mer­ck surges on Keytru­da/chemo com­bo while Bris­tol-My­ers shares tum­ble on com­par­i­son

Mer­ck and Bris­tol-My­ers Squibb both came to AACR look­ing to score points in their long-run­ning slugfest over the lung can­cer mar­ket. Both had promis­ing re­sults, but Mer­ck’s KEYNOTE-189 was clear­ly the big win­ner this morn­ing.

Mer­ck shares $MRK gained close to 3% on its case that a com­bi­na­tion of Keytru­da with chemo of­fered sol­id, across-the-board ben­e­fits for a large seg­ment of front­line cas­es, which will go a long way to win­ning over physi­cians and patents with its 0.49 haz­ard ra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.